La vendita allo scoperto per Catalyst Pharmaceuticals dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Catalyst Pharmaceuticals. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Catalyst Pharmaceuticals (NASDAQ:CPRX) Azioni, Report sulle vendite allo scoperto

Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

CPRX

VRNA

Scopriamo i 3 titoli sanitari che potrebbero affrontare un crollo a causa di indicatori di mercato e RSI elevati.

Scopri i 3 titoli sanitari che potrebbero crollare ad agosto

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Baird analyst Joel Beatty initiated coverage on Catalyst Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with an Outperform rating and announced a price target of $28. Catalyst Pharmaceuticals shares closed at $22.62 on Monday. <a href="https://www.benzinga.com/quote/CPRX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst John Freeman initiated coverage on Expand Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Strong Buy rating and announced a price target of $135. Expand Energy shares closed at $102.87 on Monday. <a href="https://www.benzinga.com/quote/EXE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John Kim initiated coverage on Terreno Realty Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Market Perform rating and announced a price target of $71. Terreno Realty shares closed at $65.26 on Monday. <a href="https://www.benzinga.com/quote/TRNO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Vera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERA#NASDAQ">VERA</a>) with an Outperform rating and announced a price target of $49. Vera Therapeutics shares closed at $36.54 on Monday. <a href="https://www.benzinga.com/quote/VERA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Wolfe Research analyst Andy Chen initiated coverage on Oruka Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKA#NASDAQ">ORKA</a>) with an Outperform rating and announced a price target of $20. Oruka Therapeutics shares closed at $13.70 on Monday. <a href="https://www.benzinga.com/quote/ORKA/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
</ul>
Considering buying EXE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png" alt="" class="wp-image-764898" style="width:551px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/04091345/image-24.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>

Initiation

Analyst Ratings

ORKA

TRNO

VERA

This Expand Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts' ratings for Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) over the last quarter vary from bullish to bearish, as provided by 6 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Catalyst Pharmaceuticals, revealing an average target of $32.33, a high estimate of $36.00, and a low estimate of $28.00. This upward trend is evident, with the current average reflecting a 7.77% increase from the previous average price target of $30.00.
<img src="https://www.benzinga.com/files/images/story/2025/1738670427_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Catalyst Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$28.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$35.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Sudan Loganathan</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Catalyst Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Catalyst Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Catalyst Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Catalyst Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CPRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Catalyst Pharmaceuticals analyst ratings.</a>
<h2>Discovering Catalyst Pharmaceuticals: A Closer Look</h2>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Catalyst Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Catalyst Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 25.33% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Catalyst Pharmaceuticals's net margin excels beyond industry benchmarks, reaching 34.1%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 5.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 6 Analysts Discuss Catalyst Pharmaceuticals Stock

Baird analyst Joel Beatty initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Outperform rating and announces Price Target of $28.

Price Target

Baird Initiates Coverage On Catalyst Pharmaceuticals with Outperform Rating, Announces Price Target of $28

Biotech

General

Catalyst Pharmaceuticals Reported That Its Sub-Licensee In Japan, Dydo Pharma, Has Launched Firdapse (Amifampridine) Tablets 10MG In Japan For The Indication Of Improving Muscle Weakness In Patients Living With Lambert-Eaton Myasthenic Syndrome

HC Wainwright &amp; Co. analyst Andrew Fein maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $35.

HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $35

B of A Securities analyst Jason Gerberry reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

Reiteration

B of A Securities Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>).
This Agreement resolves the patent litigation brought by Catalyst and its licensor SERB S.A in response to Teva&#8217;s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of Firdapse (amifampridine) 10 mg tablets before the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42881700/catalyst-pharmaceuticals-announces-settlement-of-firdapse-amifampridine-patent-litigation-with-tev" rel="noreferrer noopener">expiration of the applicable patents</a>.
If approved by the FDA, Teva will not market its generic version of Firdapse in the United States before February 25, 2035, unless certain limited circumstances customarily included in these types of agreements occur.
The parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding Firdapse patents pending in the U.S. District Court for the District of New Jersey.
The ongoing Firdapse patent litigation involves two defendants: Hetero, which is being challenged on all of Firdapse&#8217;s Orange Book-listed patents, and Lupin, which is facing a case focused on Catalyst&#8217;s Firdapse patent that expires in 2037.
In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst&#8217;s patents listed in the <a target="_blank" href="https://www.benzinga.com/news/23/01/30523209/why-catalyst-pharmaceuticals-shares-are-moving" rel="noreferrer noopener">FDA Orange Book</a>.
In May, the FDA approved its supplemental New Drug Application, increasing the indicated maximum daily dose of Firdapse&#8217;s (amifampridine) for adults and pediatric patients weighing more than 45 kg from 80 mg to 100 mg for Lambert-Eaton myasthenic syndrome (LEMS).
LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. Firdapse is a potassium channel blocker indicated for LEMS in adults and pediatric patients six years of age and older and works by increasing the release of acetylcholine, a neurotransmitter, at the neuromuscular junction, which helps improve muscle <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/g39094213/catalyst-pharmaceuticals-receives-u-s-fda-approval-for-increased-maximum-daily-dose-for-firdapse" rel="noreferrer noopener">function in people with LEMS</a>.
In the third quarter of 2024, Firdapse revenues increased 19.7% year over year to $79.3&nbsp;million. The company expects full-year 2024 net product revenue of <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41787062/catalyst-pharmaceuticals-reports-strong-third-quarter-2024-financial-results-and-provides-corporat" rel="noreferrer noopener">$300 million—$310 million</a>.
Price Action: CPRX stock closed at $19.53 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/asset-sales/25/01/42896830/clear-channel-outdoor-plans-375-million-debt-repayment-following-625-million-sale-of-european-operations" target="_blank" rel="noreferrer noopener">Clear Channel Outdoor Plans $375 Million Debt Repayment Following $625 Million Sale of European Operations</a></li>
</ul>

Large Cap

Health Care

Legal

TEVA

Catalyst Pharmaceuticals Settles Patent Litigation Case With Teva Pharmaceutical

Trading Halt: Halt status updated at 12:55:00 PM ET: Quotation Resumption: News and Resumption Times

Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. ("SERB") have entered into a Settlement Agreement (Agreement) with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc. (collectively Teva). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Teva's Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of FIRDAPSE&#xAE; (amifampridine) 10 mg tablets prior to expiration of the applicable patents.
Pursuant to the terms of the Agreement, Teva will not market its generic version of FIRDAPSE in the United States any earlier than February 25, 2035, if approved by the U.S. Food and Drug Administration (FDA), unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing patent litigation between Catalyst/SERB and Teva regarding FIRDAPSE patents pending in the U.S. District Court for the District of New Jersey. The pending FIRDAPSE patent litigation against the remaining defendants, Hetero (for all of FIRDAPSE's Orange Book-listed patents) and Lupin (only for Catalyst's FIRDAPSE patent expiring in 2037), is ongoing.
As required by law, the companies will submit the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.
 &nbsp;

Contracts

Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA

Trading Halt: Halted at 12:25:07 p.m. ET - Trading Halt: Halt News Pending

Disclosed on November 21, Patrick J McEnany, Director at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000457//Archives/edgar/data/1369568/000116169724000457/0001161697-24-000457-index.htm">U.S. Securities and Exchange Commission</a> on Thursday, McEnany sold 170,845 shares of Catalyst Pharmaceuticals. The total transaction value is $3,627,258.
Monitoring the market, Catalyst Pharmaceuticals's shares up by 1.23% at $21.38 during Friday's morning.
<h3>Discovering Catalyst Pharmaceuticals: A Closer Look</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Breaking Down Catalyst Pharmaceuticals's Financial Performance</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: Catalyst Pharmaceuticals's P/E ratio of 17.9 is below the industry average, suggesting the stock may be undervalued.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 5.59 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 9.84, Catalyst Pharmaceuticals presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Breaking Down the Significance of Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Catalyst Pharmaceuticals Insider Trades Send A Signal

Stephens &amp; Co. analyst Sudan Loganathan initiates coverage on Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Overweight rating and announces Price Target of $35.

Stephens & Co. Initiates Coverage On Catalyst Pharmaceuticals with Overweight Rating, Announces Price Target of $35

Patrick J McEnany, Board Member at Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), reported an insider sell on November 13, according to a new SEC filing. 
What Happened: After conducting a thorough analysis, McEnany sold 492,000 shares of Catalyst Pharmaceuticals. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001369568/000116169724000445//Archives/edgar/data/1369568/000116169724000445/0001161697-24-000445-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday. The total transaction value is $11,510,102.
Tracking the Thursday's morning session, Catalyst Pharmaceuticals shares are trading at $22.76, showing a down of 0.18%.
<h3>About Catalyst Pharmaceuticals</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>Key Indicators: Catalyst Pharmaceuticals's Financial Health</h3>
Revenue Growth: Over the 3 months period, Catalyst Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 25.33% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company excels with a remarkable gross margin of 85.02%, indicating superior cost efficiency and profitability compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Catalyst Pharmaceuticals's EPS is a standout, portraying a positive bottom-line trend that exceeds the industry average with a current EPS of 0.37.
</li>
</ul>
Debt Management: Catalyst Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics: A Closer Look
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 19.32 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 6.03 is lower than the industry average, implying a discounted valuation for Catalyst Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 10.79 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
Considering the legal perspective, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, according to Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Nevertheless, insider sells may not necessarily indicate a bearish view and can be influenced by various factors.
<h3>Understanding Crucial Transaction Codes</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001369568">Check Out The Full List Of Catalyst Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Catalyst Pharmaceuticals Board Member Trades $11.51M In Company Stock

Truist Securities analyst Joon Lee maintains Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and raises the price target from $30 to $36.

Truist Securities Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $36

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) with a Buy and maintains $30 price target.

HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $30 Price Target

<ul>
<li>Expect total revenues for the full year 2024 to be between $475 million and $485 million, which includes the $2.1 million milestone payment received from DyDo that is included in License and other revenue. &nbsp;</li>
<li>Revising full-year 2024 net product revenue guidance for FIRDAPSE to be between $300 million and $310 million;&nbsp;reaffirming FYCOMPA net product revenue guidance to be between $130 million and $135 million; and increasing AGAMREE net product revenue guidance to be between $40 million and $45 million, respectively. &nbsp;</li>
<li>Revising full year research and development ("R&amp;D") expense guidance to less than $15 million due to delays in the timing of certain R&amp;D related initiatives.</li>
</ul>

Guidance

Catalyst Pharmaceuticals Sees FY24 Revenue $475M-$485M Vs $473.67  Est.

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.30 by 90 percent. This is a 16.33 percent increase over earnings of $0.49 per share from the same period last year. The company reported quarterly sales of $126.42 million which beat the analyst consensus estimate of $123.42 million by 2.43 percent. This is a 23.11 percent increase over sales of $102.69 million the same period last year.

Earnings

Earnings Beats

Catalyst Pharmaceuticals Q3 Adj $0.57 Beats $0.30 Estimate, Sales $126.42M Beat $123.42M Estimate

Catalyst Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>) will release its quarterly earnings report on Wednesday, 2024-11-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Catalyst Pharmaceuticals to report an earnings per share (EPS) of $0.30.
Anticipation surrounds Catalyst Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.30, leading to a 12.75% increase in the share price on the subsequent day.
Here's a look at Catalyst Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.26</td>
<td>0.17</td>
<td>0.26</td>
<td>0.44</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.56</td>
<td>0.38</td>
<td>0.53</td>
<td>0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>13.0%</td>
<td>6.0%</td>
<td>10.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730833333_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Catalyst Pharmaceuticals were trading at $21.75 as of November 04. Over the last 52-week period, shares are up 74.24%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Observations about Catalyst Pharmaceuticals</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Catalyst Pharmaceuticals.
Catalyst Pharmaceuticals has received a total of 3 ratings from analysts, with the consensus rating as Buy. With an average one-year price target of $30.33, the consensus suggests a potential 39.45% upside.
<h3>Comparing Ratings with Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Geron, Alnylam Pharmaceuticals and Twist Bioscience, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus among analysts is an Buy trajectory for Geron, with an average 1-year price target of $6.75, indicating a potential 68.97% downside.</li>
<li>The consensus outlook from analysts is an Outperform trajectory for Alnylam Pharmaceuticals, with an average 1-year price target of $53.5, indicating a potential 145.98% upside.</li>
<li>The consensus outlook from analysts is an Neutral trajectory for Twist Bioscience, with an average 1-year price target of $52.0, indicating a potential 139.08% upside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Geron, Alnylam Pharmaceuticals and Twist Bioscience, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catalyst Pharmaceuticals</td>
<td>Buy</td>
<td>23.23%</td>
<td>$107.31M</td>
<td>6.97%</td>
</tr>
<tr>
<td>Geron</td>
<td>Buy</td>
<td>2941.38%</td>
<td>$865K</td>
<td>-20.68%</td>
</tr>
<tr>
<td>Alnylam Pharmaceuticals</td>
<td>Outperform</td>
<td>21.15%</td>
<td>$8.18M</td>
<td>82.89%</td>
</tr>
<tr>
<td>Twist Bioscience</td>
<td>Neutral</td>
<td>27.81%</td>
<td>$35.27M</td>
<td>-16.28%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Catalyst Pharmaceuticals ranks at the top for Gross Profit and Return on Equity among its peers. It is in the middle for Revenue Growth.
<h3>Unveiling the Story Behind Catalyst Pharmaceuticals</h3>
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
<h3>A Deep Dive into Catalyst Pharmaceuticals's Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Catalyst Pharmaceuticals's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 23.23%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Catalyst Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 33.24%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Catalyst Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.97% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Catalyst Pharmaceuticals's ROA excels beyond industry benchmarks, reaching 6.03%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Catalyst Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/CPRX/earnings">To track all earnings releases for Catalyst Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Catalyst Pharmaceuticals's Future Earnings

Avadel Pharmaceuticals plc (NASDAQ:AVDL) announced that the FDA has approved its supplemental new drug application (sNDA) seeking label expansion of Lumryz.
The drug is now approved in the United States for the treatment of cataplexy or excessive daytime sleepiness (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eds#NASDAQ">EDS</a>) in patients aged seven years and older with narcolepsy.
The company&#39;s shares rose 5.1% on the news.&nbsp;
The stock fell 1.4% year to date compared with the <a href="https://www.zacks.com/stocks/industry-rank/industry/medical-biomedical-and-genetics-105">industry</a>&#39;s 0.7% decline.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/97/81744.jpg?v=1324361988" style="height:245px; width:624px" /> 
Image Source: Zacks Investment Research
<h3>Label Expansion Of AVDL&#39;s Lumryz</h3>
Lumryz is a once-at-bedtime formulation extended-release sodium oxybate. It was first approved by the FDA on May 1, 2023, for the treatment of cataplexy or EDS in adult patients with narcolepsy.
Along with the approval, the FDA also granted seven years of orphan drug exclusivity to Lumryz for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of Lumryz relative to currently available oxybate treatments.
Narcolepsy is a chronic neurological condition, wherein the brain&#39;s ability to regulate the sleep-wake cycle is impaired.
The latest FDA approval expands the drug&#39;s indication for younger narcolepsy patients.&nbsp; The drug was also granted orphan drug exclusivity in pediatric narcolepsy patients aged seven years and older through Oct. 16, 2031.
Pediatric patients (seven years and older) living with narcolepsy will now have the same opportunity that adult patients with narcolepsy have &mdash; to choose a once-nightly treatment option that does not disrupt sleep for a middle-of-the-night dose.
<h3>Lumryz Uptake Boosts AVDL</h3>
Avadel generated $41.5 million of net product revenues from the sales of Lumryz in the second quarter of 2024.
As of June 30, there were more than 1,900 patients on Lumryz compared to more than 1,400 as of March 31.
Pediatric patients currently represent approximately 5% of all oxybate-treated narcolepsy patients. Hence, the label expansion of the drug for this population should boost sales.
In addition, a phase III double-blind, placebo-controlled, randomized withdrawal, multicenter study is evaluating the efficacy and safety of Lumryz in idiopathic hypersomnia (IH).&nbsp; Enrollment is open to patients who are currently being treated with a twice-nightly oxybate and those not taking oxybates. The study, which is expected to enroll approximately 150 adults diagnosed with IH, includes an open-label extension portion.
<h3>AVDL&#39;s Rank &amp; Other Stocks To Consider</h3>
Avadel carries a Zacks Rank #3 (Hold) at present.&nbsp; Some other top-ranked stocks in the drug/biotech sector are Catalyst Pharmaceuticals CPRX, ANI Pharmaceuticals ANIP and
<a href="https://www.zacks.com/stock/news/2353213/avadel-obtains-fda-nod-for-label-expansion-of-narcolepsy-drug-lumryz?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2353213">To read this article on Zacks.com click here.</a>

Small Cap

ALNY

ANIP

Avadel Obtains FDA Nod for Label Expansion Of Narcolepsy Drug Lumryz

Catalyst Pharmaceuticals, Inc.&nbsp;("Catalyst" or "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRX#NASDAQ">CPRX</a>), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that its sub-licensee in Japan, DyDo Pharma, Inc., ("DyDo") has reported that the Ministry of Health, Labor and Welfare of Japan has approved DyDo's New Drug Application ("NDA") to commercialize FIRDAPSE&#xAE; (amifampridine) Tablets 10 mg for treatment of patients with Lambert-Eaton Myasthenic Syndrome ("LEMS") in Japan. This approval marks a pivotal advancement in the treatment of LEMS, a rare autoimmune disorder that can severely impact quality of life and represents a significant step forward in addressing the unmet needs of patients affected by LEMS in Japan.
"We are pleased that our partner, DyDo, has secured regulatory approval for FIRDAPSE in Japan. This represents a meaningful milestone, bringing renewed hope to patients and further affirming FIRDAPSE's proven effectiveness in the treatment of LEMS," said Richard J. Daly, Catalyst's President and Chief Executive Officer. "This achievement underscores our unwavering commitment to advancing patient care. We appreciate the collaborative efforts of our partner in securing this approval, and we remain focused on expanding our innovative rare disease product portfolio beyond the U.S. to make a meaningful impact on patients' lives worldwide."
FIRDAPSE (amifampridine) is a leading therapy indicated in the United States for the treatment of LEMS in adults and pediatric patients six years of age and older. LEMS is a rare autoimmune disorder characterized by muscle weakness and fatigue. About 50% of people with LEMS have underlying cancer, as LEMS is observed in approximately 3% of small-cell lung cancer patients. FIRDAPSE is the only U.S. FDA-approved, evidence-based treatment for LEMS. As a cornerstone of Catalyst's commitment to serving those with rare diseases, FIRDAPSE is supported in the U.S. by a comprehensive patient support program to help ensure accessibility and assistance for eligible U.S. patients.

Government

Regulations

Catalyst Pharma's FIRDAPSE Approved in Japan for Rare Autoimmune Disorder Lambert-Eaton Myasthenic Syndrome ("LEMS")

Catalyst Pharmaceuticals: The Stars Align For Flagship FIRDAPSE

Truist Financial analyst Joon Lee maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today. The company's shares closed yesterday ...

Catalyst Pharma (CPRX) Receives a Buy from Truist Financial

What Moved Markets This Week

IYH: Healthcare Dashboard For January

Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the indicatio...

Catalyst announces sub-licensee pharma launches FIRDAPSE in Japan

An update from Catalyst Pharma ( ($CPRX) ) is now available. On January 17, 2025, Charles B. O'Keeffe, an independent member of the Board of Direct...

Catalyst Pharma Announces Board Member's Departure

The healthcare industry is set for growth due to advancements in targeted treatments and personalized care and the rapid evolution of medical technologies. Hence, investors might consider investing in niche healthcare stocks, Immunocore Holdings (IMCR), Catalyst Pharmaceuticals (CPRX), and BioCryst Pharmaceuticals (BCRX). Read more… The healthcare market is evolving due to technological advancements and global health challenges, with increasing demand for innovative solutions driven by aging populations, chronic conditions, and the shift toward value-based care.
Given this backdrop, it could be wise to consider investing in fundamentally strong healthcare stocks, Immunocore Holdings plc (<a href="https://stocknews.com/stock/IMCR/">IMCR</a>), Catalyst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/CPRX/">CPRX</a>), and BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>), that tackle rare diseases.
The increasing research and development (R&amp;D) in personalized medicine, numerous advancements in genetic engineering, and escalating demand for sustainable agriculture are propelling the biotech market. The global biotechnology market is expected to grow at a <a href="https://www.imarcgroup.com/biotechnology-market">CAGR of 6.3%</a> by 2033.
Additionally, the digital health market's growth is driven by ongoing technological advancements in the form of artificial intelligence, the emergence of the Internet of Things, robotics in the healthcare sector, and remote monitoring devices. The global digital health market is expected to grow at a <a href="https://www.precedenceresearch.com/digital-health-market">CAGR of 11.7%</a> by 2034.
Given these favorable industry trends, let's look at the fundamentals of three <a href="https://stocknews.com/category/biotech/">Biotech</a> stocks, starting with number 3.
Stock #3: Immunocore Holdings plc (<a href="https://stocknews.com/stock/IMCR/">IMCR</a>)
IMCR is a commercial-stage biotechnology company that engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma.
On December 3, 2024, IMCR announced that KIMMTRAK (tebentafusp) had been recommended for funding through the National Health Service (NHS) in England by the National Institute for Health and Care Excellence (NICE).
During the third quarter that ended on September 30, 2024, IMCR's total <a href="https://www.investopedia.com/terms/r/revenue.asp">revenue</a> increased 23.7% year-over-year to $80.25 million. The company's net income before income taxes of $6.09 million indicates a significant growth from the prior year's quarter.
In addition, the company's net income per share increased significantly year-over-year to $0.17.
Analysts expect IMCR's revenue for the fourth quarter (ended December 2024) to grow 20.7% year-over-year to $84.72 million.
IMCR's shares have gained 11.8% over the past month to close the last trading session at $32.61.
IMCR's prospects are reflected in its <a href="https://stocknews.com/powr-ratings/">POWR Ratings</a>. The stock has an overall rating of B, equating to a Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.
The stock has a B grade for Growth, Value, and Quality. Within the <a href="https://stocknews.com/category/biotech/">Biotech</a> industry, IMCR is ranked #23 out of 330 stocks. <a href="https://stocknews.com/stock/IMCR/">Click here</a> to access additional BDX ratings for Sentiment, Momentum, and Stability.
Stock #2: Catalyst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/CPRX/">CPRX</a>)
CPRX is a commercial-stage biopharmaceutical company that focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.
On January 21, 2025, CPRX reported that its sub-licensee in Japan, DyDo Pharma, Inc., had launched FIRDAPSE (amifampridine) Tablets 10 mg in Japan for the indication of improving muscle weakness in patients living with Lambert-Eaton myasthenic syndrome (LEMS).
For the third quarter of 2024, which ended September 30, CPRX's net product revenue increased 23.2% year-over-year to $126.42 million. The company's non-GAAP net income amounted to $71.08 million compared to a net loss of $25.64 million in the previous year's quarter.
In addition, the company's non-GAAP income per share came in at $0.60 compared to the net loss per share of $0.24 in the previous year's quarter.
Street expects CPRX's revenue and EPS for the fourth quarter (ended December 2024) to increase 21.3% and 17.2% year-over-year to $134.08 million and $0.34, respectively. Moreover, the company topped the consensus revenue and EPS estimates in three of the four trailing quarters, which is impressive.
CPRX's stock has gained 8% over the past month to close the last trading session at $23.19.
CPRX's bright prospects are reflected in its POWR Ratings. The stock has an overall rating of B, equating to a Buy in our proprietary rating system.
CPRX has an A grade for Sentiment and a B for Value and Quality. It is ranked #16 in the same industry.
In addition to the POWR Ratings we've stated above, we also have CPRX ratings for Momentum, Stability, and Growth. Get all CPRX ratings <a href="https://stocknews.com/stock/CPRX/">here</a>.
Stock #1: BioCryst Pharmaceuticals, Inc. (<a href="https://stocknews.com/stock/BCRX/">BCRX</a>)
BCRX is a biotechnology company that develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names, and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
On November 18, 2025, BCRX announced that the Health Services Executive (HSE) in Ireland had recommended ORLADEYO (berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland would have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
BCRX's total revenues increased 35% year-over-year to $117.09 million for the fiscal 2024 third quarter that ended September 30, 2024.  Its income from operations also increased to $7.69 million compared to a loss of $11.92 million in the previous year's quarter. In addition, as of September 30, 2024, BCRX's cash, cash equivalents, and investments amounted to $349.44 million, while total assets came in at $491.25 million.
The consensus revenue estimate of $131.10 million for the fiscal year quarter (ending December 2024) represents a 40.4% increase year-over-year. The company has an impressive earnings surprise history; it surpassed the consensus revenue estimates in each of the trailing four quarters.
Over the past nine months, the stock has surged 84.3%, closing the last trading session at $7.87.
BCRX's POWR Ratings reflect its bright outlook. The stock has an overall rating of B, which translates to a Buy in our proprietary rating system. 
BCRX has a B grade for Value, Quality, and Growth. It is ranked #12 in the same industry. <a href="https://stocknews.com/stock/BCRX/">Click here</a> to see the additional ratings for BCRX (Momentum, Sentiment, and Stability).
What To Do Next?
Get your hands on this special report with 3 low priced companies with tremendous upside potential even in today's volatile markets:
<a href="https://report.stocknews.com/free-report/3stocks/?formplacement=artbotad_3s">3 Stocks to DOUBLE This Year &gt;</a>

<hr />
CPRX shares closed at $22.56 on Friday, down $-0.63 (-2.72%). Year-to-date, CPRX has gained 8.10%, versus a 2.69% rise in the benchmark S&amp;P 500 index during the same period.
<hr><div style="clear:both;"></div> <h2>About the Author: Nidhi Agarwal</h2> <img src='https:/wp-content/uploads/2023/03/Nidhi-Agarwal_Headshot-3.jpg' style="float:left; padding:5px;width:125px;">Nidhi is passionate about the capital market and wealth management, which led her to pursue a career as an investment analyst. She holds a bachelor's degree in finance and marketing and is pursuing the CFA program.

Her fundamental approach to analyzing stocks helps investors identify the best investment opportunities.<a href="https://stocknews.com/authors/?author=nidhi-agarwal">More...</a>The post <a href=https://stocknews.com/news/cprx-bcrx-imcr-3-niche-healthcare-stocks-tackling-rare-diseases/>3 Niche Healthcare Stocks Tackling Rare Diseases</a> appeared first on <a href=https://stocknews.com/>StockNews.com</a>

3 Niche Healthcare Stocks Tackling Rare Diseases

Baird analyst Joel Beatty initiated coverage of Catalyst Pharmaceuticals (CPRX) with an Outperform rating and $28 price target Published first on T...

Catalyst Pharmaceuticals initiated with an Outperform at Baird

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Comments

Catalyst Pharmaceuticals

Vendite allo scoperto

Catalyst Pharmaceuticals (NASDAQ:CPRX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO